Medical treatment of Alzheimer's disease;Medicinsk behandling af Alzheimers sygdom

Ugeskrift for Laeger

Volumn 168, Issue 40, 2006, Pages 3424-3429

  Johannsen, Peter ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; DENMARK; HUMAN; LIFE EXPECTANCY;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COGNITION; DEMENTIA, VASCULAR; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; GALANTAMINE; HUMANS; INDANS; LEWY BODY DISEASE; MEMANTINE; NOOTROPIC AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33749560643     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
2. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
3. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001190. DOI: 10.1002/14651858.CD001190.
4. Birks J, Grimley EJ, Iakovidou V et al. Rivastigmine for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.
5. Olin J, Schneider L. Galantamine for Alzheimer's disease. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001747. DOI: 10.1002/14651858.CD001747.
6. Areosa SA, Sherriff F, McShane R. Memantine for dementia. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.
7. Claxton K, Neumann PJ, Araki S et al. Bayesian value-of-information analysis. An appllication to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 2001;17:38-55.
8. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
9. Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. London: Martin Dunitz Ltd, 1999.
10. Caban-Holt A, Bottiggi K, Schmitt FA. Measuring treatment response in Alzheimer's disease clinical trials. Geriatrics 2005(suppl:3-8).
11. Leber P. Criteria used by drug regulatory authorities. I: Qizilbash N, Schneider LS, Chui H et al, red. Evidence-based dementia practice. Oxford: Blackwell Science Ltd, 2002:376-87.
12. Clegg A, Bryant J, Nicholson T et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. Int J Technol Assess Health Care 2002;18:497-507.
13. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care 2000;6:S1139-S1144.
14. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004;21:607-20.
15. Winblad B, Brodaty H, Gauthier S et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-66.
16. Winblad B, Wimo A, Almkvist O. Outcome measures in Alzheimer's disease: do they go far enough? Dement Geriatr Cogn Disord 2000;11(suppl 1):3-10.
17. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
18. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
19. Gauthier SG. Alzheimer's disease: the benefits of early treatment. Eur J Neurol 2005;12(suppl 3):11-6.
20. Lopez OL, Becker JT, Wisniewski S et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-4.
21. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004;19:919-25.
22. Whitehead A, Perdomo C, Pratt RD et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004;19:624-33.
23. Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64.
24. Ritchie CW, Ames D, Clayton T et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004;12:358-69.
25. Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
26. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-9.
27. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59:817-22.
28. Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
29. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20:459-64.
30. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003;18:81-5.
31. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatmen in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
32. Frankfort SV, Appels BA, de Boer A et al. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry 2005;20:1167-71.
33. Johannsen P, Salmon E, Hampel H et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's. CNS Drugs 2006; 20: 311-325.
34. Malouf R, Birks J. Donepezil for vascular cognitive impairment. The Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004395. DOI: 10.1002/14651858.CD004395.
35. McKeith I, Del ST, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
36. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
37. Hogervorst E, Yaffe K, Richards M et al. Hormone replacement therapy to maintain cognitive function in women with dementia. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003799. DOI: 10.1002/14651858. CD003799.
38. Sano M, Ernesto C, Thomas RG et al. A controlled trail of selegiline, alphatocopherol, or both as treatment for Alzheimer's diasease. N Engl J Med 1997;336:1216-22.
39. Kurz A, van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration. Dement Geriatr Cogn Disord 2004;18:217-26.
40. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD003673. DOI: 10.1002/14651858.CD003673.